1. Home
  2. YMAB vs SIFY Comparison

YMAB vs SIFY Comparison

Compare YMAB & SIFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YMAB
  • SIFY
  • Stock Information
  • Founded
  • YMAB 2015
  • SIFY 1995
  • Country
  • YMAB United States
  • SIFY India
  • Employees
  • YMAB N/A
  • SIFY N/A
  • Industry
  • YMAB Biotechnology: Pharmaceutical Preparations
  • SIFY Computer Software: Programming Data Processing
  • Sector
  • YMAB Health Care
  • SIFY Technology
  • Exchange
  • YMAB Nasdaq
  • SIFY Nasdaq
  • Market Cap
  • YMAB 218.4M
  • SIFY 309.8M
  • IPO Year
  • YMAB 2018
  • SIFY 1999
  • Fundamental
  • Price
  • YMAB $4.04
  • SIFY $4.37
  • Analyst Decision
  • YMAB Buy
  • SIFY
  • Analyst Count
  • YMAB 11
  • SIFY 0
  • Target Price
  • YMAB $18.73
  • SIFY N/A
  • AVG Volume (30 Days)
  • YMAB 204.4K
  • SIFY 39.0K
  • Earning Date
  • YMAB 05-13-2025
  • SIFY 04-18-2025
  • Dividend Yield
  • YMAB N/A
  • SIFY N/A
  • EPS Growth
  • YMAB N/A
  • SIFY N/A
  • EPS
  • YMAB N/A
  • SIFY N/A
  • Revenue
  • YMAB $87,685,000.00
  • SIFY $466,793,915.00
  • Revenue This Year
  • YMAB N/A
  • SIFY N/A
  • Revenue Next Year
  • YMAB $18.83
  • SIFY $13.95
  • P/E Ratio
  • YMAB N/A
  • SIFY N/A
  • Revenue Growth
  • YMAB 3.38
  • SIFY 11.93
  • 52 Week Low
  • YMAB $3.84
  • SIFY $1.80
  • 52 Week High
  • YMAB $17.47
  • SIFY $10.14
  • Technical
  • Relative Strength Index (RSI)
  • YMAB 42.87
  • SIFY 50.99
  • Support Level
  • YMAB $4.02
  • SIFY $3.95
  • Resistance Level
  • YMAB $4.60
  • SIFY $4.74
  • Average True Range (ATR)
  • YMAB 0.32
  • SIFY 0.32
  • MACD
  • YMAB -0.01
  • SIFY 0.02
  • Stochastic Oscillator
  • YMAB 23.93
  • SIFY 60.64

About YMAB Y-mAbs Therapeutics Inc.

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

About SIFY Sify Technologies Limited

Sify Technologies Ltd is a provider of corporate network services in India. It offers converged Information and Communication Technology (ICT) solutions comprising Network- Connectivity services, Data Center services and Digital Services which include Cloud and Managed services, Applications Integration services and Technology Integration services. The company operates in three segments; Network Connectivity services which consists of domestic data, international data, wholesale voice. Data Center Services which consists of co-location services, cross connects and other allied managed services. Digital Services which consists of Cloud and Managed Services, Network Managed Services, Applications Integration Services, Technology Integration Services. Key revenue is from Network.

Share on Social Networks: